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were sourced from the literature. Both costs and outcomes were discounted at 
5%. Results: Incremental costs, QALYs and ICERs for canagliflozin vs. sitagliptin 
were € 1,360, 0.059 QALYs and € 23,118 per QALY, respectively, in dual therapy; € 108, 
0.093 QALYs and € 1,172 per QALY, respectively, in triple therapy; and € 550, 0.068 
QALYs and € 8,047 per QALY, respectively, in add-on to insulin. In all three scenarios, 
canagliflozin was cost-effective using the acceptable willingness-to-pay threshold in 
Ireland. Sensitivity analyses suggest that these results are robust. ConClusions: 
These simulations suggest that the use of canagliflozin in patients in need of addi-
tional glycaemic control in dual, triple and add-on to insulin lines of therapy is a 
more efficient use of health care funds than the use of sitagliptin in the Irish setting.
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objeCtives: Canagliflozin is a novel oral agent for the treatment of T2DM that 
inhibits sodium-glucose co-transporter 2 (SGLT2), a mechanism that is comple-
mentary to other anti-hyperglycaemic drug classes, including insulin. SGLT2 
inhibition leads to inhibition of glucose reabsorption and urinary glucose excre-
tion, thereby reducing blood glucose, weight, and blood pressure. An economic 
(cost-effectiveness) evaluation of new technologies versus routine care is required 
prior to uptake in Ireland to ensure good value-for-money. This study evaluates 
the cost-effectiveness of canagliflozin compared to liraglutide – a currently reim-
bursed and routinely used glucagon-like peptide 1 (GLP-1) agonist – as dual therapy 
in combination with metformin from the payer perspective in the Irish health 
care setting. Methods: The Economic and Health Outcomes Model of T2DM 
(ECHO-T2DM) [using updated UKPDS 82 mortality and risk equations] was used 
to simulate 40-year costs and outcomes associated with canagliflozin (100mg 
titrated to 300mg in patients requiring tighter glycaemic control) compared to 
liraglutide 1.2mg. Patient characteristics were sourced from canagliflozin RCTs 
in patients uncontrolled on metformin monotherapy and treatment effects were 
obtained from a network meta-analysis. The costs of treatments and outcomes 
were localised and inflated to 2013 values where possible. Utilities were sourced 
from the literature. Costs and outcomes were discounted at 5% annually. Results: 
In the base case, canagliflozin was associated with incremental cost savings of 
€ 3,382 compared to liraglutide 1.2mg. It was also associated with a 0.022 more life 
years and 0.020 more quality adjusted life years (QALYs), suggesting that cana-
gliflozin dominates liraglutide. Results were driven by lower acquisition costs for 
canagliflozin. Sensitivity analyses indicated that the dominance observed was 
robust. ConClusions: In these simulations, canagliflozin dominated liraglutide 
1.2mg in dual therapy (add-on to metformin) in the Irish setting. These results 
suggest that canagliflozin represents good ‘value for money’ in treating these 
patients, compared to a routinely used GLP-1 agonist.
PDB78
healTh eConomiC evalUaTion of Canagliflozin in The TreaTmenT of 
TyPe 2 DiaBeTes melliTUs in norWay
Troelsgaard A.1, Huetson P.2, Kjellberg J.3, Hemels M.1, Knudsen M.4
1Janssen A/S, Birkerød, Denmark, 2IMS Health, Stockholm, Sweden, 3Zefferin Farma AB, 
Stockholm, Sweden, 4IMS Health, Hellerup, Denmark
objeCtives: Canagliflozin is a novel drug for treatment of diabetes belonging to the 
drug class known as sodium glucose co-transporter 2 (SGLT2) inhibitors. To evalu-
ate the cost-effectiveness of canagliflozin in dual therapy (add-on to metformin) 
compared to sitagliptin and sulfonylurea (SU), in triple therapy (add on to metformin 
and SU) compared to sitagliptin and as add-on to insulin versus placebo. Methods: 
The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of cana-
gliflozin (using a weighted average of 80/20 for the 100 mg and 300 mg dosage, 
respectively) versus the aforementioned comparators using Norwegian-specific 
data, where available. Results: In dual therapy, as add-on to metformin versus 
sitagliptin, canagliflozin appears to dominate sitagliptin with average cost sav-
ings of 606 NOK and an average QALY gain of 0.030 and as add on to metformin 
canagliflozin is cost-effective versus SU, with an incremental cost-effectiveness 
ratio (ICER) of 79,309 NOK and an incremental cost of 5,757.80 NOK and an aver-
age QALY gain of 0.0726. As add on to insulin canagliflozin appears to dominate 
placebo with an incremental cost saving of 13,506 NOK and an incremental QALY 
of 0.080. In triple therapy as add on to metformin and SU canagliflozin appears to 
dominate sitagliptin with average cost savings of 556 NOK and an average QALY 
gain of 0.021. ConClusions: Canagliflozin is associated with cost savings and 
QALY gain compared to sitagliptin in dual therapy as add-on to metformin, and in 
triple therapy as add on to metformin and SU. Canagliflozin will be a cost-effective 
alternative to SU in dual therapy as add on to metformin. Adding canagliflozin to 
insulin will be cost-effective compared with placebo i. e. it is cost-effective to add 
canagliflozin treatment rather than not.
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objeCtives: To project the long-term costs and outcomes of sensor-augmented 
pump (SAP) with low glucose suspend (LGS) versus insulin pump alone (CSII) for 
the treatment of hypo-prone Type 1 diabetes in Slovakia. Methods: The CORE 
Diabetes Model is a peer-reviewed, validated model, which employs standard 
showed that at a willingness-to-pay threshold of £20,000 per QALY, the proposed 
treatment pathway had a 100% probability to be cost-effective. ConClusions: 
The proposed alternative treatment sequence was shown to be a cost-effective 
treatment option in patients inadequately controlled with metformin alone within 
established UK cost-effectiveness thresholds.
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objeCtives: To evaluate the long-term cost-effectiveness of liraglutide versus sit-
agliptin or exenatide, added to oral antidiabetic drug mono- or combination ther-
apy respectively, in patients with Type 2 diabetes in Greece. Methods: The CORE 
Diabetes Model, a validated computer simulation model developed to determine 
the long-term health and economic outcomes of interventions in Type 2 diabe-
tes, was adapted to the Greek health care setting. Patient and intervention effects 
data were gathered from a clinical trial comparing liraglutide 1.2mg once daily 
vs. sitagliptin 100mg once daily, both combined with metformin, and a clinical 
trial comparing liraglutide 1.8mg once daily vs. exenatide 10μ g twice daily, both as 
add-on to metformin, glimepiride or both. Direct costs were reported in 2013 Euros 
and calculated based on published and local sources. All future outcomes were 
discounted at 3.5% per annum, and the analysis was conducted from the perspec-
tive of a third-party payer in Greece. Results: Over a patient’s lifetime, treatment 
with liraglutide 1.2mg vs. sitagliptin drove a mean increase in discounted life expec-
tancy of 0.13 (SD 0.23) years and in discounted quality-adjusted life expectancy 
of 0.19 (0.16) quality-adjusted life years (QALYs), whereas therapy with liraglutide 
1.8mg vs. exenatide yielded increases of 0.14 (0.23) years and 0.19 (0.16) QALYs 
respectively. As regards lifetime direct costs, liraglutide 1.2mg resulted in greater 
costs of € 2797 (€ 1468) versus sitagliptin, and so did liraglutide 1.8mg compared 
with exenatide (€ 1302 [€ 1492]). Liraglutide 1.2 and 1.8mg doses were associated 
with incremental cost effectiveness ratios of € 15101 and € 6818 per QALY gained, 
respectively. ConClusions: Liraglutide is likely to be a cost-effective option for 
the treatment of Type 2 diabetes in a Greek setting.
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objeCtives: Canagliflozin is a novel drug for treatment of diabetes belonging to 
the drug class known as sodium glucose co-transporter–2 (SGLT-2) inhibitors. To 
evaluate the cost-effectiveness of canagliflozin 100 mg in the Slovakian setting 
from a payer perspective when compared to sitagliptin in dual therapy (add-on to 
metformin), sitagliptin in triple therapy (add-on to metformin plus sulfonylurea) and 
dapagliflozin in combination with insulin (with or without metformin). Methods: 
The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of cana-
gliflozin versus comparators using Slovakia specific data, where available. Results: 
The cost-effectiveness analyses indicated that canagliflozin 100 mg in dual therapy 
when compared with sitagliptin, was found to be cost-effective with an incremental 
cost-effectiveness ratio (ICER) of 14,930 € per QALY gained. In triple therapy when 
compared to sitagliptin, canagliflozin 100 mg was found to be cost-effective with 
an ICER of 5,251 € per QALY gained and in combination with insulin, canagliflozin 
100 mg was a dominant alternative compared to dapagliflozin with a cost saving of 
118 € per patient and higher QALYs. One-way sensitivity analyses revealed that in 
the majority of scenarios considered canagliflozin remained cost-effective in the 
dual therapy, triple therapy and add-on to insulin comparisons. ConClusions: 
Based on calculations performed using the CORE Diabetes model, canagliflozin 100 
mg appear to represent a cost-effective option for the treatment of type 2 diabetes 
in Slovakia. Canagliflozin 100 mg was found to offer greater health benefits than 
currently available alternatives and to be a cost-effective treatment option when 
used in dual and triple therapy instead of sitagliptin or as an add-on to insulin 
instead of dapagliflozin.
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objeCtives: Canagliflozin is a new oral agent for the treatment of T2DM that inhib-
its sodium-glucose co-transporter 2 (SGLT2), thereby leading to inhibition of glucose 
reabsorption and urinary glucose excretion which results in reductions in blood 
glucose, weight, and blood pressure. The purpose of this analysis was to evaluate 
the cost-effectiveness of canagliflozin vs. sitagliptin – a recommended and widely 
used dipeptidyl peptidase-4 inhibitor (DPP4) – in dual (with metformin), triple (with 
metformin + sulphonylurea) and add-on to basal insulin (with or without other 
anti-hyperglycaemic agents) therapy lines in Ireland. Methods: The Economic and 
Health Outcomes Model of T2DM (ECHO-T2DM) [using updated UKPDS 82 mortality 
and risk equations] was used to simulate lifetime outcomes and costs of patients 
on either canagliflozin (100mg, titrated to 300mg as needed to maintain glycaemic 
control) or sitagliptin 100mg. Patient characteristics and treatment effects were 
sourced from head to head randomized clinical trials for dual and triple therapy. 
For the add-on to insulin therapy simulations, treatment effects were sourced from 
a network meta-analysis. Costs were localised and inflated to 2013 euros. Utilities 
